Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of BioCentury, Week in Review: Sales and Marketing

BioCentury, Week in Review Current Issue
  • Amgen, Transgenomic sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Transgenomic Inc. (OTCBB:TBIO), Omaha, Neb. Business: Diagnostic Transgenomic launched worldwide the CRC RAScan test to screen patients with metastatic colorectal cancer (…

    Published on 5/20/2013
  • Amgen, Zhejiang Beta Pharma Co. Ltd. sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Zhejiang Beta Pharma Co. Ltd., Hang-Zhou, China Business: Cancer Amgen and Zhejiang Beta formed a JV - Amgen-Beta Pharmaceuticals Co. Ltd. - to commercialize Amgen's …

    Published on 5/20/2013
  • Anacor, Valeant Pharmaceuticals sales and marketing update

    Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Montreal, Quebec Business: Infectious Valeant said it will not launch efinaconazole to treat …

    Published on 5/20/2013
  • Igdrasol Inc., Samyang, Sorrento sales and marketing update

    Igdrasol Inc., Fountain Valley, Calif. Samyang Corp. (KSE:000070), Seoul, South Korea Sorrento Therapeutics Inc. (OTCBB:SRNE), San Diego, Calif. Business: Cancer Samyang's Samyang Biopharmaceuticals Corp. subsidiary …

    Published on 5/20/2013
  • Savient sales and marketing update

    Savient Pharmaceuticals Inc. (NASDAQ:SVNT), Bridgewater, N.J. Business: Endocrine/Metabolic Savient said in its 1Q13 earnings that it raised the wholesale acquisition cost of gout drug Krystexxa pegloticase in the U.S. …

    Published on 5/20/2013
  • Vivus, Express Scripts sales and marketing update

    Vivus Inc. (NASDAQ:VVUS), Mountain View, Calif. Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Business: Endocrine/Metabolic Vivus said obesity drug Qsymia phentermine/topiramate was added to the national …

    Published on 5/20/2013
  • Galderma sales and marketing update

    Galderma S.A., Lausanne, Switzerland Business: Dermatology Galderma launched Tri-Luma cream in the U.S. to treat moderate to severe melisma of the face for up to eight weeks. Tri-Luma is a topical combination of …

    Published on 2/18/2013
  • Hisamitsu sales and marketing update

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530; Osaka:4530), Tosu, Japan Business: Endocrine/Metabolic Hisamitsu's Noven Pharmaceuticals Inc. subsidiary launched Minivelle estradiol transdermal system in the U.S. to …

    Published on 2/18/2013
  • Hyperion sales and marketing update

    Hyperion Therapeutics Inc. (NASDAQ:HPTX), South San Francisco, Calif. Business: Endocrine/Metabolic On a Feb. 4 conference call regarding FDA's approval of Ravicti glycerol phenylbutyrate, Hyperion said it estimated a …

    Published on 2/18/2013
  • Innovus, Prospector Capital Partners II LLC sales and marketing update

    Innovus Pharmaceuticals Inc. (OTCBB:INNV), San Diego, Calif. Prospector Capital Partners II LLC, San Diego, Calif. Business: Gastrointestinal, Dermatology Innovus signed a binding term sheet to acquire nine prescription…

    Published on 2/18/2013
  • Myriad Genetics, Saladax sales and marketing update

    Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Saladax Biomedical Inc., Bethlehem, Pa. Business: Diagnostic Saladax said Myriad will return North American rights to its My5-FU diagnostic test following a …

    Published on 2/18/2013
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo Nordisk said it will launch diabetes drug Tresiba insulin degludec in Japan "shortly after" the drug is listed on Japan's …

    Published on 2/18/2013
  • Reckitt Benckiser, Bristol-Myers sales and marketing update

    Reckitt Benckiser Group plc (LSE:RB), Slough, U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Pharmaceuticals Reckitt Benckiser will acquire exclusive commercialization and distribution rights to OTC …

    Published on 2/18/2013
  • AIBioTech sales and marketing update

    American International Biotechnology LLC, Richmond, Va. Business: Diagnostic The company launched its LDT asparaginase assay in the U.S. and Canada. The assay measures L-asparaginase levels in patients receiving …

    Published on 2/11/2013
  • Astellas sales and marketing update

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Endocrine/Metabolic, Infectious Astellas said in its fiscal 3Q earnings for the period ending Dec. 31, 2012 that it launched three products. Astellas said that …

    Published on 2/11/2013
  • Biotest sales and marketing update

    Biotest AG (Xetra:BIO), Dreieich, Germany Business: Autoimmune, Diagnostic Biotest's Biotest Pharmaceuticals Corp. subsidiary launched IV Bivigam 10% human immune globulin in U.S. to treat primary immune deficiency …

    Published on 2/11/2013
  • Dyax, Novellus Biopharma AG sales and marketing update

    Dyax Corp. (NASDAQ:DYAX), Burlington, Mass. Novellus Biopharma AG, Switzerland Business: Inflammation Dyax and Novellus partnered to develop and commercialize Kalbitor ecallantide in select regions in Latin America to …

    Published on 2/11/2013
  • Oasmia, Pharmasyntez sales and marketing update

    Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Pharmasyntez, Irkutsk, Russia Business: Cancer Oasmia granted Pharmasyntez exclusive commercialization and distribution rights to Paclical micellular paclitaxel in …

    Published on 2/11/2013
  • Sequenom sales and marketing update

    Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Business: Diagnostic Sequenom said it expanded the range of chromosomal abnormalities reported by the MaterniT21 Plus laboratory-developed test (LDT) to include fetal sex …

    Published on 2/11/2013
  • Supernus sales and marketing update

    Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Business: Neurology Supernus launched Oxtellar XR oxcarbazepine in the U.S. as an adjunctive therapy in the treatment of partial seizures in adults and …

    Published on 2/11/2013
  • Amarin sales and marketing update

    Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Business: Cardiovascular Amarin said it launched Vascepa icosapent ethyl in the U.S. as an adjunct to diet to reduce triglyceride levels in adults with severe …

    Published on 2/4/2013
  • Arup Laboratories, Counsyl Inc. sales and marketing update

    Arup Laboratories, Salt Lake City, Utah Counsyl Inc., South San Francisco, Calif. Business: Diagnostic Arup partnered with Counsyl to include the Counsyl Test in Arup's pre-pregnancy and early pregnancy genetic test …

    Published on 2/4/2013
  • D&A Pharma, Imaxio sales and marketing update

    D&A Pharma, Paris, France Imaxio S.A., Saint-Beauzire, France Business: Endocrine/Metabolic D&A granted Imaxio rights to congenital metabolic disease drug Trolovol d-penicillamine in France. The chelator is marketed in …

    Published on 2/4/2013
  • Epigenomics, Predictive Biosciences sales and marketing update

    Epigenomics AG (Xetra:ECX), Berlin, Germany Predictive Biosciences Inc., Lexington, Mass. Business: Diagnostic The partners said Predictive Biosciences launched a biopsy test to diagnose prostate cancer in the U.S. that…

    Published on 2/4/2013
  • Exelixis sales and marketing update

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Business: Cancer Exelixis launched Cometriq cabozantinib in the U.S. to treat progressive, metastatic medullary thyroid cancer (MTC). The wholesale acquisition …

    Published on 2/4/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?